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Abstract
Experts project that by 2050, 10 million lives will be lost annually as a result of
antimicrobial resistant infections, surpassing all current leading causes of death, and
costing the global economy $100 trillion USD on healthcare efforts. To promote
research and development of novel antibiotics, the World Health Organization and
Centers for Disease Control and Prevention released a list of priority pathogens
regarded as serious or urgent threats of antimicrobial resistance. Many pathogenic
bacteria, including several priority pathogens, produce O-acetylated peptidoglycan to
establish infection and avoid host immune responses. Consequently, the enzymes
responsible for producing O-acetylated peptidoglycan in Gram-negative pathogenic
bacteria, peptidoglycan O-acetyltransferase A and B (PatA/PatB), are recognized as a
virulence factor. In this thesis, the identification of aurintricarboxylic acid, purpurin, and a
presumed degradation product of compound 89224 (a benzothiazolyl-pyrazolo-pyridine
from the ChemBridge Collection) are presented as amongst the first known inhibitors of
PatB from Neisseria gonorrhoeae (NgPatB). Additionally, several residues on NgPatB
were identified to be essential for O-acetyltransferase activity using a surrogate
peptidoglycan acetyl-acceptor, as well as making significant interactions with the
identified inhibitors. This thesis serves as a foundation upon which novel broadspectrum inhibitors of peptidoglycan O-acetyltransferases and O-acetylesterases can
be derived, ultimately allowing the possibility to mitigate the threats of antimicrobial
resistance.
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1. Introduction
1.1 Antimicrobial resistance
The discovery of penicillin1 and sulpha drugs,2 and their subsequent use from the
1940’s marked the dawn of the ‘Golden Era’ of antibiotic discovery3 that enabled the
control of Gram-positive pathogens, such as Staphylococcus, and enhanced therapeutic
practices like chemotherapy (Figure 1).2 With the increasing discovery and development
of antibacterial agents, threatening procedures, such as invasive surgeries, became
routine, and life expectancy and quality improved substantially. Five main classes of
antibiotics emerged in the golden era, targeting the synthesis of the bacterial cell-wall,
folate, proteins, DNA, and RNA.3 However, no new classes of antibiotics have been
discovered since the 1980’s, marking what is referred to as the ‘discovery void’ (Figure
1).4 Antibiotic discovery has been limited due to common research and development

Figure 1. Illustration depicting the history of antibiotic discoveries, highlighting the pre-antibiotic era
(blue), the ‘golden era’ of drug discovery (gold), and the ‘discovery void’ (red). The information depicted
was extracted from ref 4.

6

practices along with the emergence of antimicrobial resistance (AMR) as a result of
many issues, such as the increased demand for antibiotics in agriculture, poor sanitary
practices, and improper drug prescription.5 When pathogenic bacteria are exposed to
antimicrobial drugs, the strains able to survive the stressful conditions induced by the
antibiotics are able to reproduce with a lack of competition in their environment, thus
leading to the emergence of “superbugs”, such as methicillin-resistant Staphylococcus
aureus (MRSA).5 Recently, the World Health Organization (WHO) and Centers for
Disease Control and Prevention (CDC) published a list of priority pathogens regarded
as serious or urgent threats requiring research and development to discover novel
antibacterial agents and reduce the risk that AMR poses (Table 1).6,7 Currently, an
estimated 700,000 lives are lost every year as a result of drug-resistant infections and is
predicted to rise to 10 million lives annually by 2050; surpassing all current leading
causes of death (Figure 2), and costing the global economy $100 trillion USD on
healthcare efforts.5 The economic impact of such an outcome would be comparable to
the 2008 global financial crisis as a result of the costs associated with health care
expenditures and recovery efforts.8 The consequences of neglecting this truth are
deadly and immediate action must be taken. The extensive review on AMR recently
conducted by the UK government estimated that investing $3-4 billion per year (circa.
0.05% of the current spending on healthcare from the G20 countries) into global health
action against AMR can avert the impending consequences of AMR.5 Steps, such as
improving disease surveillance, water quality, hygiene, waste removal and sanitation,
correcting the overuse and misuse of antimicrobials, and the discovery and

7

Table 1. List of Gram-negative and Gram-positive bacterial species that produce O-acetylated PG
(known and hypothetical based on genomic analysis). Information was extracted from ref 48 and
represents only a subset of identified species. Highlighted are pathogens regarded as serious or
urgent threats from the WHO and CDC that are known (red) or predicted (black) to produce Oacetylated PG based on genomic analysis.

development of novel antimicrobial agents, can help achieve this. The success of the
golden era stemmed from the discovery of antibiotics derived from natural products,3
but the discovery void has shown that these common methods may no longer serve
their purpose and new methods for the discovery and development of novel
antibacterial agents must be implemented. Aside from different approaches to modern
8

Figure 2. Illustration of the projected rise of annual deaths related to antimicrobial resistance (AMR)
surpassing all current leading causes of death by 2050. The information depicted was extracted from
ref 5.

drug discovery, discussed in reference 3, new methods must be explored. One such
method includes the discovery of “non-traditional” antibacterial agents that target
virulent bacterial components without affecting those that are necessary for bacterial
growth.9 In theory, this approach may delay the development of resistance.
Congruently, novel antibacterial targets must also be exploited to propel these efforts.
Such potential new targets include enzymes involved in peptidoglycan (PG)
metabolism.

1.2 Peptidoglycan structure
PG is a cell wall co-polymer unique to prokaryotic organisms (nearly all bacteria)
that forms a mesh-like sacculus that surrounds the cell.10–12 PG is chiefly composed of
alternating monomeric units of N-acetylglucosamine (GlcNAc) and N-acetylmuramic
acid (MurNAc) bonded through a β (1→4) glycosidic linkage, with a terminating non9

Figure 3. Structure of PG comprising a terminal 1,6-anhydro-MurNAc residue along with highlighted
differences between the stem-peptides in Gram-negative bacteria (based on N. gonorrhoeae) and Grampositive bacteria (based on S. aureus).

reducing 1,6-anhydro-MurNAc residue in Gram-negative and some Gram-positive
bacteria (Figure 3).10,11 The composition of the polymer is generally conserved among
different bacterial species, but the polymeric chain length is found to vary with bacterial
strain and culture conditions,13,14 and can be highly variable, ranging on average,
between 50 to 250 disaccharide units as found in Bacilli, 18 disaccharide units as found
in Staphylococcus aureus, or even as low as below 10 disaccharide units in
Helicobacter pylori.15–18 To aid in the strength and structural needs of the PG sacculus,
oligopeptide strands consisting of three to five alternating L- and D-amino acids are
incorporated into the structure at the C3 lactyl moiety of MurNAc residues by peptide
10

bonds (Figure 3). This modification to PG provides a source for inter-strand peptide
crosslinking (transpeptidation) and creates the mesh-like features of the PG sacculus.
Both Gram-negative and Gram-positive bacteria modify PG from the C3 lactyl
moiety of MurNAc residues beginning with L-Ala and D-Glu, at positions 1 and 2,
respectively, and are capped with two D-Ala residues at positions 4 and 5. Release of
either, both, or just the terminal D-Ala residue(s) results as a by-product of PG
maturation through the action of endogenous carboxypeptidases. 19 The third position of
the oligopeptide consists of a diamino acid, which is directly involved in transpeptidation
and carries the most variability between bacterial species. In Gram-negative bacteria,
meso-diaminopimelic acid (mDAP) is commonly found, whereas in Gram-positive
bacteria L-Lys is most common, along with a bridging peptide, such as penta-glycine of
Staphylococcus aureus, that is covalently bonded to the terminal ε-amino group of LLys. Transpeptidation results in a direct linkage via a peptide bond between the amino
group of the diamino acid at position three and the carboxyl group of the fourth D-Ala
residue of neighboring strands.

1.3 Peptidoglycan biological significance
The PG sacculus is essential for retaining cell structure and rigidity, maintaining
the inner turgor pressure of the cell, acting as a scaffold for anchoring extracellular
components (such as surface polymers), as well as providing a barrier to foreign
species and chemicals from the outer environment.20 Through Gram-staining, bacteria
can be characterized as either Gram-negative or Gram-positive based on the
characteristics and structure of their cell wall (Figure 4).21 Gram-negative bacteria
contain one to three layers of PG (<10 nm thick) sandwiched between a cytoplasmic
11

Figure 4. Illustration of the differences between Gram-negative and Gram-positive bacterial cell
envelopes. Gram-negative cell envelopes contain a cytoplasmic and outer membrane, the latter retaining
LPS, sandwiching a thin layer of PG in the periplasm. Gram-positive cell envelopes contain a thick PG
layer that encompasses a cytoplasmic membrane and retains WTA and LTA (not shown).

inner membrane and an outer membrane.20 The outer membrane retains
lipopolysaccharides (LPS) that extend into the outer environment and are important for
maintaining the structural integrity of the cell, protecting the cell from chemical attack,
and increasing the stability of the membrane.22,23 Interestingly, depending on the
composition of the outer portion of LPS, the cell may be more susceptible to
hydrophobic antibiotics.24,25 Gram-positive bacteria contain multiple layers of PG (30100 nm thick) that encompasses the cytoplasmic membrane.20 Lipoteichoic acids (LTA)
are anchored into the cytoplasmic membrane and extend into the PG layer, while PG
retains wall-teichoic acids (WTA) that extend to the outer surface of the PG layer. 22
LTAs are important for maintaining a continuum of anionic charge along the surface,
regulating the activity of autolysins, and binding to target cells, such as receptors.22
Similarly, WTAs also help to regulate autolytic activity, as well as provide rigidity to the
cell wall, and can even be decorated with alanine residues or glucosamine to give the
molecule zwitterionic properties.20,22,26
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The integrity of the PG sacculus is critical to preserve cell viability, especially in
Gram-negative bacteria containing only a few layers of PG. Accordingly, PG metabolism
has been the target for many successful antibacterial drugs, such as the β-lactams
(e.g., penicillin) and glycopeptides (e.g., vancomycin), which inhibit cell wall
transpeptidation, effectively compromising the integrity of the PG sacculus and leading
to cell death. The enduring success of these drugs demonstrates the effectiveness of
antibacterial drugs targeting the PG structure. With that in mind, it is not surprising that
bacteria devote the consumption of many resources and employment of many systems
to preserving its protective PG sacculus.

1.4 Peptidoglycan metabolising enzymes
While PG retains the turgor pressure of the cytoplasm and subsequently the
structure of the cell, bacterial cells still require the metabolism of PG polymer strands for
the insertion of extracellular components, such as flagella and surface proteins, as well
as for bacterial division. Many endogenous lytic enzymes exist in bacteria that function
to maintain the PG sacculus, such as N-acetylmuramyl-L-alanine amidases (MurNAc-LAla amide bond hydrolysis), endopeptidases (peptide amide bond cleavage) and
carboxypeptidases (peptide bond hydrolysis),19 however the focus here will be on two
main PG murolytic enzymes, the lytic transglycosylases (LTs) and lysozyme.
The LTs constitute endogenous PG degrading enzymes in Gram-negative
bacteria. Although LTs are present in Gram-positive bacteria, they have not been shown
to be a significant contributor in PG metabolism. In general, LTs catalyze the acid-base
cleavage of the β (1→4) glycosidic bond between MurNAc and GlcNAc producing a
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Figure 5. Illustration depicting the action of lysozyme and lytic transglycosylases (murolytic enzymes),
and their respective products of PG lysis. O-acetylation of PG MurNAc residues prevents the action of
murolytic enzymes.

terminal non-reducing 1,6-anhydroMurNAc product (Figure 5).27,28 This lysis is required
to control the chain length of PG strands during biosynthesis as well as provide sites for
the insertion of wall-spanning complexes, such as flagella and transport systems
without compromising the integrity of the PG sacculus.27,29
Lysozyme is produced as a defensive or predatory bacteriolytic enzyme by
Eukaryotes and represents the principle component of the host immune response to
bacterial infection in many species, including humans.30 It is a muramidase, present in
human serum, tears, saliva, milk, and mucus, and consists of three main types,
including c-type (chicken or conventional type), g-type (goose type), and i-type
(invertebrate type), which differ by amino acid sequence and biochemical and
enzymatic properties.30 The focus here will be c-type, represented by hen egg-white
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lysozyme. Similar to LTs, lysozyme acts to cleave the β (1→4) glycosidic linkage
between MurNAc and GlcNAc residues. Different from the LTs, lysozyme is a hydrolase
that utilizes a catalytic Glu and Asp catalytic dyad to hydrolyse the β (1→4) glycosidic
bond producing a terminal reducing MurNAc residue,30,31 thereby compromising the
integrity of the cell wall and concomitantly the viability of the cell (Figure 5).
Without a mechanism of control for endogenous LTs or invading lysozyme at the
substrate level, the polymeric chains of PG would not have a chance to develop, and
persistent lytic activity would jeopardize the PG sacculus ultimately leading to cell death,
explaining in part why lysozyme is a principal component of the host immune system.
One method by which bacteria can forestall exogenous lytic activity and to provide a
means of endogenous lytic regulation is through the physical or chemical modification of
PG. These modifications can include the insertion of teichoic acid or
lipopolysaccharides in the cell wall or membrane, respectively, as well as covalent
modifications directly to the PG disaccharide units.12,32

1.5 Peptidoglycan modifications
No known bacterial species contains a strictly unmodified PG sacculus.12
Concomitant modification to mature PG upon the polymerization of disaccharide chains
is essential for the preservation of the sacculus, as well as establishing infection by
pathogens.33 Contrarily, given that PG is unique to bacteria, mammalian pattern
recognition receptors recognize important structural motifs of PG fragments produced
from the action of lysozyme, which initiates an immune response.34 Heretofore
mentioned, the addition of WTA to GlcNAc or MurNAc residues, as well as the
production of a 1,6-anhydro ring on terminal MurNAc residues, are both observed as
15

cell wall modifications.20,27,29,32 Common modifications to PG are summarized in Figure
6. The focus here is on the O-acetylation of MurNAc residues, commonly referred to as
“PG O-acetylation” (Figures 5-6).

Figure 6. Common modifications to PG involving GlcNAc (top) and MurNAc (bottom) are shown in cyan
with reference to the unmodified disaccharide (middle).

1.6 O-acetyl-peptidoglycan pathobiological significance
PG O-acetylation, the product of which is commonly referred to as “O-acetyl-PG”,
describes the addition of an acetyl group to the C6 hydroxyl moiety of MurNAc residues
by an ester linkage in mature PG (Figures 5-6). This modification was first identified by
Abrams in Streptococcus faecalis ATCC 9790 (now Enterococcus hirae ATCC 9790),35
and Brumfitt et. al in Micrococcus luteus,36 who described the association of the
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presence of O-acetylated PG with an increased resistance to hen egg-white lysozyme.
Since its discovery, a plethora of Gram-negative and Gram-positive bacterial species
that produce O-acetyl-PG have been recognized (Table 1). Interestingly, this
modification has been observed extensively in many pathogenic strains of bacteria
including S. aureus (both methicillin and vancomycin resistant (MRSA and VRSA,
respectively)), Streptococcus pneumoniae, and Neisseria gonorrhoeae, indicating that
this modification is utilized by pathogens specifically to avoid host immune response,
where commensal non-pathogenic bacteria lack this modification. It should be noted
that some pathogenic bacteria do not produce O-acetyl-PG, such as Escherichia coli,
and Pseudomonas aeruginosa.37 One alternative method to control the lytic activity of
lysozyme and the LTs in Gram-negative pathogens that do not produce O-acetyl-PG
includes the use of the proteinaceous inhibitors such as Ivy.38,39 In 2006, Bera et. al
showed that only pathogenic, lysozyme resistant, species of staphylococci were Oacetylated at the C6 hydroxyl position of MurNAc residues, and all non-pathogenic
strains lacked this modification and thus were sensitive to lysozyme.40 These results
underscore the potential of targeting PG O-acetylating systems in the search for novel
antibacterial/antivirulence targets.
The extent of O-acetylation, which varies between species, strain, and with the
age and conditions of a culture, ranges from 20 to 70% with respect to MurNAc
content,41,42 and has been shown to be directly correlated with lysozyme resistance.43
Interestingly, in response to the treatment of vancomycin-resistant Enterococcus
faecalis with vancomycin, the O-acetylation of PG increases and may indirectly cause
increased virulence and transmittance in both the treated patient and in the healthcare
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setting.44 Exacerbating the problem, the treatment of MRSA with vancomycin leads to
the emergence of vancomycin-resistant enterococci as an alternate pathogen.44
Moreover, the persistence of large molecular weight fragments of O-acetyl-PG in the
circulatory system has been linked to causing downstream pathobiological effects, such
as rheumatoid arthritis,45 and was shown to play an important role in the severity and
persistence of septic arthritis from S. aureus in mouse models.46 Additionally, Sanchez
et. al (2017) showed that fragments of O-acetyl-PG limit the priming of helper T cells,
thus interfering with the host-immune response and permitting reinfection of S. aureus.47
By virtue of the properties of O-acetyl-PG in pathogenic bacteria, O-acetyl-PG is
recognized as a virulence factor by means of proportionally increasing resistance to
host-immune system responses, such as that of lysozyme.13 Consequently, the systems
responsible for the O-acetylation of PG are recognized as desirable targets for the
discovery of novel antibiotics.

1.7 O-acetyl-peptidoglycan physiological significance
In Gram-negative bacteria, O-acetylation of PG at the MurNAc residue acts as a
steric hinderance to prevent the productive binding of murolytic enzymes. This includes
the endogenous LTs that help to control the metabolism of PG, as well as lysozymes of
host immune system responses (Figure 5).13,48 With the LTs, in addition to sterically
hindering productive binding, the presence of the 6-O-acetyl modification totally
precludes enzymatic activity as a free hydroxyl group at this position is required for its
mechanism of action (further discussed below). Instead of LTs, Gram-positive bacteria
produce endogenous β-N-acetylglucosamidases, which hydrolyze the β (1→4) linkage
between GlcNAc and MurNAc residues.19 Importantly, the cleavage of PG between
18

MurNAc and GlcNAc versus between GlcNAc and MurNAc is an important distinction
with regards to productive binding and concomitant enzymatic mechanism, and so the
action of the LTs and β-N-acetylglucosamidases are not equal. LTs and lysozyme,
albeit sharing the same site for PG cleavage, are mechanistically distinct (Figure 7).27,30

Figure 7. Mechanism of cleavage of PG across the β-1,4-glycosidic linkage between MurNAc
and GlcNAc residues through hydrolysis (lysozyme) and by production of 1,6-anhydroMurNAc
(lytic transglycosylases).
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Thus, the O-acetylation of MurNAc residues in Gram-positive bacteria does not affect
the activity of β-N-acetylglucosamidases and accordingly, this modification appears to
act strictly as a defense mechanism against lysozyme. Consequently, Gram-negative
bacteria also require an O-acetyl-PG esterase for the removal of acetyl groups from
MurNAc residues, providing a means for controlled PG metabolism by permitting access
of the endogenous LTs to the β (1→4) linkage between MurNAc and GlcNAc
residues.32

1.8 Enzymes and pathways of peptidoglycan O- and de-O-acetylation
The addition of O-acetyl groups to alginate – an exopolysaccharide found in P.
aeruginosa – is dependent on several genes, including that of algI – a gene encoding a
membrane-bound O-acyl transferase (MBOAT) protein.49 In 2005, the genome of N.
gonorrhoeae was probed, and a three-gene operon named O-acetyl-PG (OAP) was
found to contain an AlgI paralog.50 Given that N. gonorrhoeae does not produce
alginate, it was proposed that this gene was responsible for encoding a membranebound protein that functions to O-acetylate PG. This activity was confirmed and so the
protein product was subsequently named peptidoglycan O-acetyltransferase A (PatA).50
Directly downstream of the patA gene, a gene encoding for a proposed O-acetyl-PG
esterase was discovered, comprising a member of the SGNH hydrolase superfamily,
named O-acetylpeptidoglycan esterase 2 (Ape2).50
Later, it was determined that Ape2 was in fact responsible for PG O-acetylation,
not as the proposed esterase, and to follow convention, it was suitably renamed
peptidoglycan O-acetyltransferase B (PatB; Figure 8). The discovery of PatB provided
evidence supporting a two-component model of PG O-acetylation in Gram-negative
20

Figure 8. Genetic organization and domain structure of the O-acetyl-PG (OAP) cluster encoding
enzymes involved in PG O-acetylation (PatA/B, OatA) and de-O-acetylation (Ape1) in Gram-negative
and Gram-positive bacteria. Abbreviations include MBOAT, membrane-bound O-acetyltransferase;
SGNH, SGNH family of esterases; CBM, carbohydrate-binding module; and Acyl_Transf_3,
acyltransferase family 3.

bacteria (PatA/PatB).51 This marked the first discovery of a PG O-acetyltransferase in a
Gram-negative bacterium, using N. gonorrhoeae as the representative species. Notably,
downstream of the patA and patB encoding genes in the OAP cluster, a third gene,
ape1, was recognized to encode a true O-acetyl-PG esterase named Ape1, along with
an appended family 35 carbohydrate binding module (CBM35; Figure 8).52
The initial translocation of acetyl groups from the cytoplasm to the periplasm is
presumably facilitated by PatA; it is presumed that cytoplasmic pools of acetyl-CoA
provide a sufficient supply of acetyl groups, and that PatA directly hands off an acetyl
group to PatB, or via an acetylated periplasmic intermediate (Figure 9). However,
experimental evidence of the cytoplasmic source(s) of acetyl groups and the
mechanism of translocation from the cytoplasm through to PatB remains unknown.
Provided that PatA is an integral membrane protein, its expression and purification has
21

Figure 9. Proposed pathway for the O-acetylation and de-O-acetylation of PG in Gramnegative bacteria. Acetyl groups from an unknown source are presumably translocated
through the cytoplasmic membrane by PatA and presented to PatB in the periplasm to Oacetylate PG. Ape1 is involved in the catalytic de-O-acetylation of O-acetylated PG.

remained unsuccessful; this work is currently being followed up in the Clarke lab.
Furthermore, to balance the amount of O-acetylation, thereby controlling the rate of PG
metabolism, Ape1 is utilized as an O-acetyl-PG esterase for the removal of O-acetyl
groups (Figure 9).32 Exactly how the activity of O-acetylpeptidoglycan transferases
(PatA/B) and esterases (Ape1) are controlled to allow sufficient O-acetylation for
lysozyme resistance and cell viability, while still maintaining control over PG metabolism
remains unknown.53
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In 2013/2014, the first kinetic and biochemical characterization of PatB from N.
gonorrhoeae (NgPatB) revealed the proposed catalytic mechanism of PG Oacetyltransferases (Figure 10).54–56 NgPatB O-acetylates PG through a ping-pong bi-bi
mechanism with an acyl-enzyme intermediate, utilizing a Ser-His-Asp catalytic triad and
oxyanion stabilizing residues spread across four consensus sequence block motifs
(Blocks I-III and V) characteristic of the SGNH hydrolase family.48,54,57,58 The acidic
Block V Asp294 residue regulates the amphoteric nature of the Block V His297 that
removes the proton from the hydroxyl group of the catalytic Block I Ser125 rendering it
nucleophilic (panel (i) in Figure 10). The 3-dimensional organization of these residues is
essential to enable the nucleophilic potential of the catalytic Ser.59

Figure 10. The catalytic mechanism of NgPatB (grey) displaying the catalytic triad (Ser125, His297,
Asp294) and oxyanion hole residues (Ser125 and Ser153 backbone amide, Asn188 sidechain amide),
with pNP-Ac as a representative acetyl-donor (cyan panel (i)-(iii), acetyl in green) and MurNAc as a
representative acetyl-acceptor (cyan panel (iv)-(vi)). NgPatB undergoes a ping-pong bi-bi mechanism
between free-enzyme (i, vi), tetrahedral oxyanion transition states (ii, v), an acyl-enzyme intermediate
(iii-vi), and release of acetylated-acceptor substrate (v-vi). The structure of NgPatB depicted here was a
gift from A. Brott.
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The nucleophilic Ser attacks the electrophilic carbonyl carbon of the acetyl
moiety from an acetyl-donor (panel (i)). The backbone amide of the catalytic Ser and the
Block II Ser153, along with the sidechain amide of the Block III Asn188 create an
oxyanion hole that stabilizes the tetrahedral oxyanion transition state (panel (ii)), and
increases electrophilicity of the acetyl donor, which is then prone to attack by the
catalytic Ser nucleophile. The collapse of the oxyanion produces an acetyl-enzyme
intermediate (panel (iii)). The C6 hydroxyl moiety of a MurNAc residue in a mature
strand of PG would then be rendered nucleophilic by His proton abstraction, allowing
nucleophilic attack of the acyl-enzyme intermediate (panel (iv)), forming a second
tetrahedral oxyanion transition state (panel (v)), and finally O-acetylation of the MurNAc
residue and release of free NgPatB (panel (vi)).60 Biochemical analysis of NgPatB
demonstrated a substrate specificity for chitooligosaccharides containing ≥3 degrees of
polymerization (DP; GlcNAc≥3) and muro-tetrapeptide strands of both di- and
tetrasaccharides, confirming the role of PG O-acetylation as a maturation event,
occurring after transglycosylation and transpeptidation.60
In Gram-positive bacteria, an analogous system to PatA/PatB is utilized
containing proteins that comprise an Acyl_Transf_3 (AT3) domain appended to an
SGNH hydrolase domain (Figure 8).61 Acetyl groups are presumably translocated
across the cytoplasmic membrane by the N-terminal AT3 domain (OatAN) where the Cterminal SGNH domain (OatAC) O-acetylates the C6 hydroxyl of MurNAc residues.57,61
Similar to PatA, OatAN has not yet been structurally characterized, and the presumably
cytoplasmic source(s) of acetyl groups, along with the mechanism of translocation of
acetyl groups through the cytoplasmic membrane have not been determined. Recently,
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the structures of OatAC from S. aureus (SaOatAC; PDB id 6VJP)62 and S. pneumoniae
(SpOatAC; 5UFY)61 were elucidated. The mechanism of O-acetylation was determined
to be a ping-pong bi-bi mechanism, similar to NgPatB, utilizing a nucleophilic Ser, part
of a Ser-His-Asp catalytic triad, along with the backbone amide of the catalytic Ser and
the Block II residue, as well as the sidechain amide of the Block III Asn forming an
oxyanion hole to stabilize the tetrahedral oxyanion intermediates and increase
electrophilicity of the carbonyl carbon on the acetyl donor.57 For the first time, it was
experimentally shown that the substrate specificity for SaOatAC and SpOatAC was
active on only glycans containing DP ≥4 (GlcNAc≥4).61 Moreover, SaOatAC has a high
specificity for glycan chains possessing pentapeptide strands and is therefore
presumably active only after transglycosylation and preceding transpeptidation, while
SpOatAC has highest specificity for muroglycans possessing a tetrapeptide stem and
presumably acts only after the crosslinking of mature PG.

2. Research significance
With the release of the WHO and CDC’s list of priority pathogens regarded as
serious or urgent threats (Table 1),6,7 experts project a rise to 10 million lives lost
annually by 2050 as a direct result of antimicrobial resistance (Figure 2), costing the
global economy $100 trillion USD on healthcare efforts.5 Immediate action must be
taken towards the research and development of novel antibiotics, ideally exploiting new
antibacterial/antivirulence targets to propel drug discovery efforts.
O-Acetylation of the C6 hydroxyl moiety of MurNAc residues has been observed
to occur in a plethora of pathogenic bacteria (Table 1),48 and is predominantly used to
confer lysozyme resistance and establish infection, as well as for a means of
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endogenous autolytic control in Gram-negative bacteria. Several of the pathogens listed
by the WHO and CDC regarded as priority pathogens are known to produce Oacetylated PG (Table 1).6,7,13 Fittingly, the enzymes catalyzing the O-acetylation of PG
(PatA/B, OatAN/C) have been recognized directly as virulence factors,40,63–65 and thus
represent novel targets for antibiotic discovery.48 Enzymes constitute favourable targets
for antibiotic drug development by virtue of their diverse physiological roles and high
degree of substrate specificity,66 thus an antibiotic must be unique and specific towards
its target enzyme.51 Ideally, novel inhibitors of O-acetylation would work directly as
bactericidal agents by sensitizing the bacterial cell wall to rampant lytic activity.
Interestingly, inhibitors can also presumably work synergistically with currently used
antibiotics, such as β-lactams, as it was shown that the inactivation of the gene
encoding for an OatA homolog in S. pneumoniae strain Pen6 (penicillin resistant)
results in a significant reduction of the minimum inhibitory concentration of penicillin.67
As described by A. Brott et al. (2019), “inhibitors [of PG O-acetyltransferases (PatA/B
and OatAN/C)] would be expected to (i) act as anti-virulence factors to render pathogens
more susceptible to the host immune system; (ii) possibly act synergistically with
existing antibiotics that depend on autolysins for their bactericidal effect, especially the
β-lactams; (iii) potentially act directly as bactericidal agents by removing LT control
thereby permitting rampant and catastrophic autolysis; (iv) be less susceptible to efflux
as the targets are either periplasmic or external in Gram-negative and Gram-positive
pathogens, respectively; and (v) be ineffective against the predominantly non-Oacetylated commensal microbiota”.68 In that regard, the PG O-acetyltransferases
represent exemplary antibacterial/antivirulence targets because, as P.J. Moynihan et al.
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(2014) states, “(i) their PG substrate is unique to, but common amongst, almost all
bacteria; (ii) the MurNAc-GlcNAc substrate residues remain consistent in all PGs; (iii)
the lack of variation in the glycan chain decreases opportunity for resistance to evolve,
at least involving substrate modification such as seen with [Vancomycin-resistant
Enterococci]; (iv) they are required to control PG metabolism and, in the case of Grampositive bacteria, provide protection from the lysozyme activity of innate immune
systems; and (v) a mechanism-based inhibitor for any one of the enzymes will likely
prove to be reactive against all in the same way that β-lactams bind all PG
transpeptidases, albeit with varying affinities”.32
A greater understanding of the structural and mechanistic details of PG Oacetyltransferases is required to aid in the discovery and development of novel
antibiotics. Likewise, many questions remain unanswered, such as the characterization
of PatA and OatAN; representative structural and kinetic characterization of Pat and Oat
homologs from a variety of pathogenic strains; what the presumably cytoplasmic
source(s) of acetyl groups is in each case; and the full mechanistic details of acetyl
transfer (from the initial source of acetyl groups to O-acetylated-PG). In particular, the
characterization of the integral membrane domains would elicit information about
potential mechanisms of acetyl translocation across the cytoplasmic membrane, and in
turn, what the initial cytoplasmic acetyl-donor may be. Furthermore, a crystal structure
of PatB in complex with a substrate or bioisostere (a small-molecule that contains
similar physical or chemical properties to the actual substrate in vivo) would offer insight
into the spatial arrangements within and around the active site with respect to enzymesubstrate interactions. This would serve to identify points to enhance chemical binding
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interactions in the development of inhibitors, as well as to gain insight into the
mechanistic details of acetyl transfer in vivo. Since the PG O-acetyltransferases and Oacetylesterases are mechanistically indistinguishable, only their acetyl donors and
acceptors would differ; with PG and O-acetyl-PG being one of the co-substrates and coproducts (for PatB/OatAC), or vise versa (for Ape). Presumably, this would allow for the
potential broad-spectrum inhibition of these enzymes using inhibitors comprising related
underlying scaffolds.

3. Hypotheses and research aims
Previously, it was demonstrated that the use of para-nitrophenol acetate (pNPAc) as an acetyl-donor for the kinetic analysis of NgPatB inhibition by identified
compounds produced vastly different results compared to using 4-methylumbelliferyl
acetate (4MU-Ac). I hypothesize that using the same acetyl-donor substrate with two
distinct modes of analysis would provide more reliable results rather than using different
acetyl-donor substrates. Thus, my first aim was to develop and optimize in vitro assay
conditions with the aim to analyze NgPatB esterase and transferase activity using the
same acetyl-donor substrate (4MU-Ac), along with the surrogate PG acetyl-acceptor
tetraacetyl chitotetraose (GlcNAc4; given the demonstrated substrate specificity of
NgPatB for chitooligosaccharides containing ≥3 DP) as the acetyl-acceptor in
transferase assays, while monitoring the fluorogenic and chromogenic response of the
hydrolyzed product, 4-methylumbelliferone (4MU), for a direct comparison of observed
inhibition from identified small-molecule inhibitors.
My second hypothesis was that recent high-throughput screening techniques
would lead to the identification of small-molecules as amongst the first known inhibitors
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of NgPatB. These small-molecules could then be examined to determine common
underlying scaffolds and important functional groups to develop stronger inhibitors. With
this, preliminary studies would be conducted to show the potential for broad-spectrum
inhibition of structurally related enzymes including O-acetyltransferases and Oacetylesterases using the identified inhibitor(s).
My last hypothesis was that select identified amino acid residues in NgPatB are
important for its esterase and/or transferase activity. I will test this by replacing
predicted residues through site-directed mutagenesis of ngpatB, and biochemically
characterizing the resultant NgPatB variants for both their activity and inhibition by the
identified inhibitors. With these results, the chemical structures of the inhibitors could be
further optimized to increase their interactions with the identified residues to develop
stronger inhibitors.
In this thesis, I present (i) optimized conditions for the analysis of NgPatB in vitro
esterase and transferase activity; (ii) my findings in the aim of identifying small-molecule
scaffolds for the inhibition of NgPatB O-acetyltransferase activity; and (iii) my findings
pertaining to the structure-function relationship of functional residues on NgPatB, and
important enzyme-inhibitor interactions.
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4. Materials and Methods
4.1 Engineering of NgPatB construct
A recombinant construct of NgPatB from N. gonorrhoeae was developed by other
members of the Clarke lab as described.68 To provide a brief summary, the initial
construct lacked 69 residues at the N-terminus (NgPatBΔ69) and was engineered to
include a gene encoding an N-terminal His6-SUMO tag which was sub-cloned from the
Champion™ pET-SUMO expression vector (Thermo Fischer Scientific, Waltham, MA,
USA) by polymerase chain reaction (PCR) amplification.68 The PCR amplicon was
digested using appropriate restriction enzymes and ligated to a digested pBAD-His A
plasmid containing the gene for PatBΔ69 using T4 DNA ligase (New England Biolabs,
Ltd., Whitby, ON, Canada) resulting in the pACAB1 construct. pACAB1 was modified to
remove the restriction site between sumo and ngpatBΔ69 and a fusion protein was
encoded. pACAB1 excluding the restriction site was amplified by PCR and ligated using
T4 DNA ligase to generate a new construct, named pACAB2, which was used in the
production of NgPatBΔ69 containing an N-terminal His6-SUMO fusion tag. A final 31
codons were removed from the 5′ end of ngpatBΔ69, which was amplified by PCR and
ligated using T4 DNA ligase resulting in the final construct NgPatBΔ100SUMO, named
pACAB7, and provided to me as a gift from A. Brott (Figure 11). This construct was
used to produce a stable derivative of NgPatB, lacking 100 amino acids from the Nterminal (NgPatBΔ100) and possessing an N-terminal His6-SUMO fusion tag. NgPatBΔ100
is referred to as NgPatB in this thesis.
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Figure 11. Circular topology of the arabinose inducible, ampicillin resistant, pACAB7
plasmid used to express recombinant NgPatBΔ100 with an appended N-terminal His6SUMO fusion tag.
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4.2 Site-directed mutagenesis
Custom oligonucleotides were designed to contain the specific mutation of
interest (Table 2) on the Benchling molecular biology application (benchling.com, San
Francisco, CA, USA) and purchased from Integrated DNA Technologies (idtdna.com).
PCR was used to amplify the 5 kb pACAB7 template plasmid including the primers, and
the amplicons were visualized by agarose (1% w/v) gel electrophoresis using
MIDORIGREEN Direct (NIPPON Genetics EUROPE, Duren, Germany; Figure 12). After
PCR amplification, the products were incubated for 1 h at 37ºC with DpnI restriction
enzyme to selectively remove methylated template plasmid DNA that does not contain
the variant primer sequence. Successfully cloned DNA was transformed into DH5α and
BL21 Star competent E. coli cells (DE3; Novagen, Millipore (Canada) Ltd., Etobicoke,
ON, Canada) and plated onto Luria-Bertani (LB; Difco; Fischer Scientific, Ottawa, ON,
Canada) agar supplemented with 100 µg/mL ampicillin, overnight at 37ºC. Single
colonies were then incubated with 5 mL of LB broth supplemented with 100 µg/mL
ampicillin, with agitation and aeration overnight at 37ºC. Using the GeneJET Plasmid
Miniprep Kit (Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania), plasmid DNA
was isolated and purified, and then sequenced at the Genomics Facility of the
Advanced Analysis Center, University of Guelph. The resulting genetic sequence(s)
were analyzed using the Benchling molecular biology platform to confirm that the
plasmid contained the correct mutation (Figure 13). The cells were stored at -80ºC in
50% aqueous glycerol until required.

32

Table 2. NgPatB variant primers used in this thesis.

F denotes forward primer, R denotes reverse primer, underline denotes site of mutation.

Figure 12. 1% w/v agarose gel electrophoresis of plasmids encoding each of the NgPatB variants used in
this thesis. The lanes include (1,3,5,7,10) 1 kb DNA ladder; (2) WT NgPatB template plasmid (pACAB7);
(4) Q128G plasmid; (6) Q152A plasmid; (8) Q152N plasmid; (9) Q152E plasmid; and (11) K293A plasmid.
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Figure 13. Visualization of translated sequences as sequenced by the Genomics Facility of the Advanced
Analysis Center, University of Guelph, including the appropriate mutations to encode NgPatB comprising
the Q128G, Q152A, Q152N, Q152E, and K293A replacements, respectively, along with their respective
WT sequence for comparison.

4.3 Expression and purification of NgPatB
As previously described,68 cells were grown in 1 L of LB broth supplemented with
100 µg/mL ampicillin, with agitation and aeration at 37ºC until an optical density
measured at 600 nm (OD600) of circa. 0.6 was reached. The cells were then induced
with a final concentration of 0.2% L-arabinose and incubated for another 4 h before the
cells were harvested by centrifugation (5000 × g, 25 min, 4ºC). Cell pellets were
resuspended into 20 mM sodium phosphate buffer, pH 7.8, containing 500 mM NaCl
and 10 mM imidazole (wash buffer), and then subjected to lysis by circa. 20 µg/mL
DNase, circa. 20 µg/mL RNase, circa. 50 µg/mL hen egg-white lysozyme, and one
crushed ethylenediaminetetraacetic acid (EDTA) free protease inhibitor pellet. Cell lysis
was ensured by sonication (50% amplitude, 10:20 s pulse, 15 min, on ice). Insoluble
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cellular debris was cleared by centrifugation (25,000 × g, 25 min, 4ºC) and the resulting
supernatant was filtered through a 0.45 µm syringe filter (Millipore). The filtered
supernatant, containing recombinant NgPatBΔ100, was purified using Ni2+-NTA
(nitrilotriacetic acid) immobilized metal ion affinity chromatography (IMAC) by incubating
in cOmplete His-Tag purification resin with agitation at 22ºC for 1 h. The resin was then
washed in a gravity-flow column with 10 mM imidazole wash buffer, and NgPatBΔ100
was eluted after incubating with wash buffer containing 400 mM imidazole with agitation
at 22ºC for 1 h. Recovered protein was dialyzed first in 20 mM sodium phosphate, pH
7.8, containing 50 mM L-arginine overnight at 22ºC, and then in 20 mM sodium
phosphate, pH 7.8, for a minimum of 3 h, using a 12-14 kDa molecular weight cut-off
(MWCO) membrane.
Cleavage of the SUMO tag from recombinant NgPatB was achieved by
incubating the dialyzed protein with purified SUMO protease (Ulp1) at 30ºC for 3 h with
light agitation. The protein was then concentrated by centrifugation (4000 × g, 10 min,
4ºC) using an Amicon Ultra-15 10 kDa MWCO centrifugal filter (Millipore). Finally, the
sample was purified by cation-exchange (CE) chromatography using a Source mono S
column (GE Healthcare Life Sciences, Mississauga, ON, Canada). The protein was
applied and bound to the 10 × 100 mm column pre-equilibrated in 20 mM sodium
phosphate, pH 7.8, and eluted with a linear gradient of 0.1-0.3 M NaCl over 30 min.
NgPatB generally eluted at a conductivity of above circa. 28 mS/cm. Fractions were
collected throughout the protocol and assessed using the Precision Plus Protein Dual
Color Standards (Mississauga, ON, Canada) with sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE; Figure 14). Appropriate fractions were
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Figure 14. SDS-PAGE analyses of the purification of NgPatB (top), and all variant plasmids used in this
thesis (bottom). Lanes include from top: (1) Protein standard ladder; (2) cell lysate pellet; (3) cell lysate
supernatant; (4) IMAC flow-through; (5) IMAC wash; (6) IMAC elution; (7) FPLC CE flow-through (SUMO);
and (8) FPLC CE elution (purified NgPatB). From bottom: (1,8,10,13) Protein standard ladder; and
NgPatB variants including (2) WT; (3) Q128G; (4) Q152A; (5) S153A; (6) F161A; (7) R289G; (9) Q303G;
(11) Q152ESUMO; (12) Q152NSUMO; and (14) K293A. Some lanes were manually adjusted for brightness
and contrast due to the low quantity of protein that was purified.

pooled, and dialyzed overnight in 20 mM sodium phosphate, pH 7.8, at circa. 22ºC. The
described sequence of buffer exchanges was necessary to stabilize NgPatB in solution,
where exchange into lower ionic strength buffers leads to the precipitation of the protein.
Additionally, the isolation of NgPatB by cation exchange after cleavage of the N-terminal
His6-SUMO fusion tag was enabled by the use of buffer at pH 7.8 as NgPatB is
predicted to have a isoelectronic point (pI) of 8.75,51 and the His-tag remains neutral at
this pH.

36

4.4 Quantification of NgPatB
NgPatB was quantified using a Pierce™ BCA Protein Assay Kit (Thermo Fischer
Scientific, Waltham, MA, USA). Albumin (BSA) standards were prepared by diluting a 2
mg/mL BSA stock into Milli-Q water to obtain a standard curve with seven standard
concentrations ranging from 125-2,000 µg/mL. Working reagent (WR) was prepared by
mixing 50 parts of BCA Reagent A (sodium carbonate/bicarbonate, bicinchoninic acid,
and sodium tartrate in 0.1 M NaOH) with 1 part BCA Reagent B (4% cupric sulphate). In
a 96-well microtiter plate (Costar 3997), 10 µL of purified NgPatB and BSA standards
were each mixed with 200 µL of the WR (sample to WR ratio = 1:20) in triplicate. The
plate was mixed thoroughly on a plate shaker for 30 seconds, and then incubated at
37ºC for 30 min. The plate was then allowed to cool to circa. 22ºC, and the samples
were measured for their absorbance at 562 nm on a Synergy H1 Microplate Reader
(BioTek). The concentration of NgPatB was deduced through linear regression of the
standard curve, commonly yielding 1.0-1.5 mg/mL of purified protein. Purified NgPatB
was aliquoted and stored at -20ºC until required.

4.5 NgPatB enzymatic assay conditions
All assays were carried out in 96-well microtiter plates (Costar 3997) and
monitored in a Synergy H1 Microplate Reader (BioTek). NgPatB esterase activity was
monitored to determine the quality of the assay by analysis of the Z’-factor using
equation (1)69 :

(1)

Z’-factor = 1 –

3σh+3σl
| µh−µl |
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where σh, σl, µh, and µl are the standard deviations (σ) and averages (µ) of the high (h,
100% activity, negative) and the low (l, 0% activity, positive) controls. Greater
separation between the standard deviations establishes a higher quality assay, where
replicates that fall within three standard deviations (3σ; z-score ≥ |3|) of the high and low
average controls (µh/µl) represent confident results. Z’-factor was scored between 0
and 1, where 1 represents complete separation between controls. A score of 0.6 ≤ Z’ is
deemed suitable for reliable and reproducible use in assays. The assay conditions
employed in this thesis were developed through the monitoring of the Z’-factor to
achieve a factor of ≥0.6 for reliable and reproducible results.
The conditions of all esterase reactions included well concentrations of 1.2 µM
NgPatB in 50 mM sodium phosphate buffer, pH 7.0 and 20% v/v DMSO. Activity was
monitored at 25ºC and analyzed between 4-10 min after the addition of the acetyl-donor
substrate through the chromogenic and fluorogenic hydrolysis products of the
substrates including up to 5.0 mM pNP-Ac (pNP) and up to 2.0 mM 4MU-Ac (4MU)
using absorbance at 405 nm and fluorescence at λex = 390 nm and λem = 420 nm,
respectively. A chromogenic assay was also developed to measure 4MU at 355 nm in
the same conditions. Assays measuring the transferase ability of NgPatB were carried
out in the same conditions, except with 10% v/v DMSO, 3.5 mM pNP-Ac, and between
0.02-2.0 mM tetraacetyl chitotetraose, a surrogate PG acetyl-acceptor. Transferase
activity was calculated by subtracting background hydrolysis and esterase activity using
a control lacking the acetyl-acceptor substrate, with the assumption being that such
background activity will continue to occur when in the presence of acceptor
substrates.55 The specific activity of NgPatB and NgPatB variants were carried out in
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the same conditions with 3.5 mM pNP-Ac, and 1.0 mM tetraacetyl chitotetraose for
transferase assays. To determine the half-maximal inhibitory concentration (IC50) and
mode of inhibition of potential inhibitors, 1-500 µM and 10-100 µM of inhibitor,
respectively, along with a control lacking inhibitor, were incubated with NgPatB for 10
min prior to the addition of the acetyl-donor substrate. All kinetic parameters were
determined by nonlinear regression analysis using GraphPad Prism 9 (GraphPad
Software, San Diego, CA, USA, www.graphpad.com).

4.6 In silico docking
Using AutoDockTools-1.5.6. (The Scripps Research Institute)70 I uploaded a PDB
structure of NgPatB into AutoDockTools, deleted all water molecules, added all
hydrogens to the structure, merged non-polar hydrogens, and then assigned partial
charges by using the “compute gasteiger” function, providing a rigid PDB file of the
ligand receptor. Next the PDB file of a GlcNAc-MurNAc(pentapeptide)-GlcNAcMurNAc(pentapeptide) ligand was extracted from its complex with an E503Q variant of
Slt lytic transglycosylase from Pseudomonas aeruginosa (6FCS),71 and edited in
PyMOL 2.3.2 (pymol.org) to GlcNAc-MurNAc(dipeptide)-GlcNAc-MurNAc(dipeptide) to
reduce the complexity of the ligand. The ligand was then converted from PDB format to
AutoDock PDBQT format using OpenBabelGUI 2.3.1 (softpedia.com) and input into
AutoDockTools where the torsion tree root was detected by selecting the “detect root”
command. Next, under the “grid” command, the NgPatB structure was chosen as the
macromolecule, converting it into a rigid PDBQT file, and the GlcNAcMurNAc(dipeptide)-GlcNAc-MurNAc(dipeptide) was selected as the ligand. The
covalent map was then setup, centering the map on the sidechain oxygen of the
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nucleophilic Ser125 residue, and reducing the energy barrier height to 1000 and the
half-width to 5.00 Å. The grid box was centered on the sidechain oxygen of the
nucleophilic Ser125 residue, and manually expanded to allow sufficient probing of the
ligand around the active site residues of interest. The output was saved as a GPF file,
and used to run autogrid, which prepared the macromolecule for autodocking by precalculating the interaction energies for various atom types on the macromolecule. Next,
under the “docking” command, the macromolecule PDBQT file produced by autogrid
was set as the rigid macromolecule receptor, and the GlcNAc-MurNAc(dipeptide)GlcNAc-MurNAc(dipeptide) was selected as the ligand. A genetic algorithm was
selected for the search parameters with up to 40 runs, and medium number of
evaluations. The output was selected as a Lamarckian genetic algorithm, saved as a
DPF file, and used to run autodock. The Lamarckian genetic algorithm allowed for
flexible ligand-receptor docking using complex ligands with many rotatable bonds
through a stochastic optimization method.72 After autodocking was complete, I analyzed
all docked conformations ranked by energy. Upon visualization of the docking
conformations, I selected the conformation that best represented a presumably true
conformation where the ligand was not significantly strained, and with the C6 hydroxyl
group of a MurNAc group positioned in the active site within a few angstroms of the
catalytic Ser nucleophile. Once the docking confirmation was selected, it was
downloaded in PDBQT format and input into PyMOL, where further translational and
rotational editing of the structure was done to provide a more observably realistic
confirmation, the final of which is shown in Figure 21C.
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4.7 Multiple sequence alignment
Using T-Coffee (ebi.ac.uk; EMBL-EBI, Wellcome Genome Campus, Hinxton,
Cambridgeshire, UK), the sequence of NgPatBΔ100 was aligned with homologous PatB
sequences from the Gram-negative species listed in Table 1. Important to note, the
sequence of NgPatB used in this multiple sequence alignment (MSA) is lacking 100
amino acids from the N-terminal of the wildtype sequence, so the amino acids displayed
on the MSA appear 100 residues short of what is discussed in this thesis (e.g., Ser25
on the MSA is equivalent to Ser125 as discussed). The MSA was visualized using
ESPript 3.0 (espript.ibcp.fr).73 The reference secondary structure was depicted on the
MSA using the structure of NgPatB that was provided as a gift from A. Brott. The MSA
is included in Appendix 1, Figure A1.

5. Results and Discussion
5.1 Optimization of NgPatB enzymatic assays
First, the optimal concentration of NgPatB was determined by varying the final
concentration from 0.8-2.4 µM in 50 mM sodium phosphate buffer, pH 7.0 and 5% v/v
dimethyl sulfoxide (DMSO) at 25°C (Table 3). DMSO was used as a solvent for all
acetyl-donor substrates and inhibitors. Activity was monitored through the chromogenic
and fluorogenic hydrolysis products of the acetyl-donor substrates pNP-Ac (pNP) and
4MU-Ac (4MU) using absorbance at 405 nm and fluorescence at λex = 390 nm and λem
= 420 nm, respectively. A chromogenic assay was also developed to monitor 4MU at
355 nm in the same conditions. It was determined that using a concentration of 1.2 µM
NgPatB was optimal for all assay conditions with Z’-factors of ≥0.75 (Table 3). Notably,
concentrations of 4MU-Ac >0.5 mM in 5% v/v DMSO lead to the precipitation of the
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Table 3. Z'-factor of varying concentrations of NgPatB.

Abs. denotes absorbance, Fl. denotes fluorescence.

substrate, and thus the enzyme could not be saturated without compromising the
reliability and reproducibility of the measured response. I then varied the amount of
DMSO present in the reaction from 5-30% (Figure 15). It was determined that up to 2.0
mM of 4MU-Ac was required to sufficiently saturate NgPatB, and thus 20% v/v DMSO
was used in all assays. The measured Z’-factor of NgPatB esterase activity with 20%

Figure 15. Effect of DMSO on the specific activity of NgPatB as an esterase with pNP-Ac as
substrate.

42

v/v DMSO was sufficient at ≥0.85 (Table 3). Next, the pH of the reaction was varied
from 6.0-8.0 using 50 mM Bis-Tris buffer (pH 6.0), 50 mM sodium phosphate buffer (pH
7.0), and 50 mM Tris buffer (pH 8.0) to monitor the hydrolysis of pNP-Ac. The
determined Z’-factors and specific activities are shown in Table 4. In acidic conditions,
NgPatB loses the ability to efficiently hydrolyse pNP-Ac with a specific activity of 6.6 ±
0.3 nmolꞏmin-1ꞏmg-1. In basic conditions, while NgPatB retains the ability to efficiently
hydrolyze pNP-Ac (specific activity of 367.6 ± 6.5 nmolꞏmin-1ꞏmg-1) and has a Z’-factor
of 0.80, the substrate is prone to spontaneous hydrolysis which may result in a high
background in the control reactions. For these reasons, 50mM sodium phosphate, pH
7.0, was used in all assays, with a sufficient specific activity of 246.4 ± 4.8 nmolꞏmin 1ꞏmg-1

and the highest Z’-factor of 0.82. The last condition that I optimized was the

range of time that was used to incubate the reaction. The Z’-factor of pNP-Ac hydrolysis
was monitored in blocks of 5 min for one hour at pH 6.0 to determine an optimal range
to analyze the activity of NgPatB (Table 5). A pH of 6.0 was necessary to avoid
Table 4. Z'-factor of NgPatB esterase activity over varying pH.a
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Table 5. Z'-factor of NgPatB esterase activity over varying reaction times.a

spontaneous hydrolysis and thus high background, as well as concomitant
undersaturation of NgPatB, over the length of the reaction. Analysis between 5-10 min,
10-15 min, and 15-20 min of reaction time produced Z’-factors of 0.81, 0.78, and 0.84,
respectively. From this, all analyses in this thesis, including the aforementioned, were
conducted between 4-10 minutes of reaction time because of the high Z’-factor, efficient
reaction time, and sufficient time range for reliable analysis.

5.2 Identification of small-molecule inhibitors of NgPatB
Previous results. The Clarke lab recently developed a high-throughput screen
(HTS) for the identification of small molecule inhibitors of NgPatB.68 In a pilot HTS to
validate its usefulness, 3,921 compounds from the Canadian Compound Collection
Bioactive Subset were tested in duplicate in a fluorometric assay for their inhibitory
effect of NgPatB esterase activity using 4MU-Ac as substrate. Additionally, a secondary
large-scale HTS was developed; 14,400 compounds from the Maybridge HitFinder
Collection, 50,000 compounds from the ChemBridge Collection, and 4,480 compounds
from the GlycoNET ChemBridge Collection were tested under the same conditions. Hits
were identified as any compound for which both threshold criteria of ≥20% inhibition and
a z-score of ≤-3.0 were met. A z-score represents the number of standard deviations
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that a datum lies from the mean of the control data. Identified hits were validated in
triplicate using the fluorometric in vitro assay monitoring 4MU-Ac hydrolysis at λex = 390
nm and λem = 420 nm. Compounds that represented pan-assay interference compounds
(PAINS)74 were eliminated, and the remaining were further validated in fluorescence
interference (quenching) assays to dismiss false positives. From these screens, two
leads were identified: (i) compounds containing a coumarin core; and (ii) compound
89224 from the ChemBridge Collection, a benzothiazolyl-pyrazolo-pyridine (Figure 16).
The IC50 of all compounds were determined in dose-response fluorogenic and
chromogenic assays with 4MU-Ac and pNP-Ac as the acetyl-donor substrate,
respectively. Additionally, a Lineweaver-Burke plot indicated competitive inhibition for
the coumarins and a mixed/non-competitive inhibition for compound 89224.68
Interestingly, the IC50 values differed substantially between both substrates used,
where that of 4MU-Ac hydrolysis was an order of magnitude less than that of pNP-Ac
hydrolysis. This was hypothesized to be due to the competition of the coumarin

Figure 16. Hit window of select coumarins and compound 89224 identified from the initial highthroughput screen for NgPatB. The information depicted was extracted from ref 67 with edits to include
only select coumarins and compound 89224.
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derivatives with the structurally similar 4MU-Ac substrate for the active site of NgPatB
compared to that of pNP-Ac, which is presumed to fit into the active site easily and thus
difficult to inhibit. These observations are compounded as well by analysis of the
Michaelis-Menten kinetic parameters of 4MU-Ac hydrolysis, which was measured to
have an overall catalytic efficiency (kcat/Km) of 98.3 ± 13 M-1s-1, whereas pNP-Ac
hydrolysis was measured to have an overall efficiency of 214 ± 8.0 M-1s-1, over twice as
efficient.68 Moreover, 4MU-Ac was observed to have a 6-fold lower Km (0.49 ± 0.06 mM)
than pNP-Ac (2.96 ± 0.07) indicating that 4MU-Ac exhibits more and/or stronger binding
interactions in the active site. To confirm the identity of true inhibitors and avoid false
positive results, the assay conditions needed to be optimized for the hydrolysis of 4MUAc and pNP-Ac, respectively.
Current studies. The first step in my approach to resolve these outstanding
issues was to optimize in vitro assay conditions for the esterase activity of NgPatB for
the hydrolysis of 4MU-Ac and pNP-Ac and to utilize this to confirm apparent leads
identified from the HTS. Optimizing the assay conditions, as described above in section
4.6, all esterase reactions comprised well concentrations of 1.2 µM NgPatB in 50 mM
sodium phosphate buffer, pH 7.0, and 20% v/v DMSO. Activity was monitored at 25ºC
and analyzed between 4-10 min after the addition of the acetyl-donor substrate through
the chromogenic and fluorogenic hydrolysis products of the substrates including up to
5.0 mM pNP-Ac (pNP) and up to 2.0 mM 4MU-Ac (4MU) using absorbance at 405 nm
and fluorescence at λex = 390 nm and λem = 420 nm, respectively. Given the
discrepancy between the measured IC50 using 4MU-Ac and pNP-Ac as substrate, a
chromogenic assay was also developed to measure the absorbance of 4MU at 355 nm
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in the same conditions. Assays measuring the transferase ability of NgPatB were
carried out in the same conditions measuring the hydrolysis of 3.5 mM pNP-Ac with
absorbance at 405 nm, except with 10% v/v DMSO and between 0.02-2.0 mM
tetraacetyl chitotetraose, a surrogate PG acetyl-acceptor. The specific activity of
NgPatB and NgPatB variants were carried out in the same conditions with 3.5 mM pNPAc, and 1.0 mM tetraacetyl chitotetraose for transferase assays. To determine the halfmaximal inhibitory concentration (IC50) and mode of inhibition, 1-500 µM and 10-100 µM
of inhibitor, respectively, along with a control lacking inhibitor, were incubated with
NgPatB for 10 min prior to the addition of the acetyl-donor substrate.
Interestingly, monitoring the chromogenic response of hydrolyzed 4MU-Ac
yielded nearly a 12-fold increase in catalytic efficiency (61.1 ± 0.1 M-1s-1) compared to
that of the fluorogenic response (5.2 ± 0.1 M-1s-1). Notably, given that NgPatB is not a
natural esterase, the concentration of 4MU-Ac that is required to achieve a reproducible
rate above sensitivity limits exceeds critical well concentrations, where it was
demonstrated that exceeding circa. 0.2 mM 4MU inherently quenches the fluorescent
signal and leads to a non-linear response of 4MU-Ac hydrolysis (Figure 17). This finding

Figure 17. Fluorescent response of increasing 4MU demonstrating a
non-linear relationship above concentrations exceeding 0.2 mM 4MU.

47

poses a significant effect that contributed to the realization that the discovery of the
coumarins and compound 89224 as inhibitors of NgPatB may have been a false
positive result. To confirm these speculations, I tested the strongest known coumarin
inhibitors (esculetin and esculin – 2 and 3 in Figure 16) for their inhibitory effect of 4MUAc and pNP-Ac hydrolysis, measuring absorbance of the hydrolysis products at 405 nm
and 355 nm, respectively. It was discovered that inhibition of NgPatB only became
relevant at inhibitor concentrations exceeding circa. 300 µM, as compared to that of 10
µM when measuring the fluorescent response of 4MU-Ac hydrolysis (Figure A2,
Appendix 1). Moreover, concentrations of 4MU-Ac exceeding 0.5 mM in <5% v/v DMSO
(pilot HTS conditions), or 2 mM in <20% v/v DMSO lead to the precipitation of the
substrate and consequently irreproducible and unreliable results. For these reasons, I
suspended the use of 4MU-Ac as an acetyl-donor substrate in vitro aside from
confirming potential hit compounds from the HTS. It was determined through these
findings that the coumarins and compound 89224 were in fact false positives from the
initial HTS, as they are much weaker inhibitors than initially claimed. Interestingly, the
coumarins discovered as inhibitors of NgPatB displayed strong inhibitory effects to other
homologs of NgPatB, such as that from Proteus mirabilis using pNP-Ac as the acetyldonor substrate (A. Anderson, personal communication). These findings are currently
being followed up in the Clarke lab.
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With compound 89224, I observed that a stock solution dissolved in 100% DMSO
visibly changed colour from a bright orange to dark green after remaining on the bench
top at ambient conditions for over 1 year (Figure 18A inset right). To encourage the
unknown reaction to go to completion, a portion of the green coloured sample was
heated at 100ºC for 4 days, after which it took on a deep red colour (Figure 18A inset
right). UV-Vis spectroscopy confirmed this observation (Figure 18A) and what is
presumed to be a degradation product of compound 89224. The inhibitory effect of the
aged/heated products (green/red) significantly exceeded that of fresh compound 89224
(orange) when measuring the hydrolysis of pNP-Ac using NgPatB (Figure 18B).
To determine if the colour change was due to the acidification of the sample,
potentially from the dissolution of carbon dioxide and/or water vapour, concentrated HCl

Figure 18. (A) UV-Vis spectrum of stock solutions of compound 89224 (orange), aged compound 89224
(green), and heated compound 89224 (red), along with the structure of compound 89224 (left inset) and a
visual image of the samples corresponding to their colour in the spectrum (right inset). (B) Dosedependence of inhibition of NgPatB pNP-Ac hydrolysis by compound 89224 (orange) and aged/heated
compound 89224 (green) as compared to the baseline activity control with no inhibitor (red). The
concentration of the aged/heated compound may be overestimated given its purity remains unknown. The
stars in B represent a p value ≤0.01 (**) and ≤0.0001 (****).
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and NaOH were added dropwise to a portion of aged (green) compound 89224. Upon
the addition of HCl, the sample turned a light peach colour and a precipitate formed.
The addition of NaOH shifted the colour back to green and the precipitate dissolved.
Unfortunately, since compound 89224 was dissolved into 100% DMSO, initial pH values
were not determined, nonetheless these observations are indicative of the potential role
of pH on the colour, solubility, and possibly the structural composition of this unknown
compound. Together with the observed inhibition of aged compound 89224 in the assay
conditions described (pH 7.0), it is presumed that the compound may bear a negative
charge at basic pH and proposes the importance of an anion to inhibit the activity of
NgPatB. Still, the identity of the exact chemical species responsible for the observed
inhibition remains elusive. Attempts to identify the chemical species responsible for the
observed inhibition could include several techniques, such as mass spectrometry,
nuclear magnetic resonance spectroscopy, and thin-layer chromatography.
To continue the search for potent inhibitors of NgPatB, I turned to the work of
Pfeffer et. al. (2012) where a HTS similar to that of NgPatB was utilized to identify the
first known inhibitors of NgApe1.75 Given that Ape1 and PatB share the same catalytic
fold and machinery, are mechanistically indistinguishable, and are active on the same
substrates both in vivo (PG) and in vitro (pNP-Ac, 4MU-Ac), this presented a great
opportunity to leverage these results into potentially identifying potent inhibitors of
NgPatB. Among the several inhibitors identified for Ape1, aurintricarboxylic acid (ATA)
and purpurin were discovered to be strong inhibitors of NgPatB with IC50 values of 5.6 ±
0.4 µM and 37.2 ± 7.7 µM, respectively (Figure 19; Figure A2, Appendix 1).
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Figure 19. First known inhibitors of NgPatB (purpurin and aurintricarboxylic acid)
and structural analogues tested in this thesis.
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Additionally, ellagic acid also displayed strong inhibition, however this inhibition
was incomplete and only reached circa. 37% residual activity, where up to 500 µM
ellagic acid was unable to completely inhibit NgPatB activity (Figure A2, Appendix 1).
Consequently, ellagic acid was not considered further. ATA and purpurin were both
further investigated along with structural analogues to identify potentially more potent
inhibitors and important functional groups essential for enzyme-inhibitor interactions.
The first structural analog of purpurin, quinalizarin (Figure 19), only reduced the
esterase activity of NgPatB by 50% at 500 µM, where quinizarin, the second structural
analog, only reduced the activity by 35% at 500 µM. While not obvious at first, this vast
difference in inhibitory effects between the purpurin analogues was uncovered by a
previous member of the Clarke lab (2015),76 where it was described that the structure of
purpurin permits a relatively low pKa of the C2 hydroxyl moiety of 4.7 (Figure 20) and
thus would significantly reside in its anionic form at pH 7.0. It follows that quinalizarin,
with a pKa of its C2 hydroxyl group of 6.6, would still bear a negative charge at pH 7.0,
albeit in much smaller amounts relative to purpurin, and thus displayed weaker inhibition
than purpurin, yet stronger inhibition than quinizarin which lacks a C2 hydroxyl group,

Figure 20. Structures of purpurin, quinalizarin, and quinizarin displaying the pKa value of their respective
C2 hydroxyl groups (C1 hydroxyl for quinizarin). With assays being conducted at pH 7.0, purpurin is
presumably the only structure of the three to possess an anionic charge in significant amounts.
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and instead bears a C1 hydroxyl group with a pKa of 10.8. Consequently, these results
suggest that the presence of an anion is required for the inhibition of NgPatB. This
presumption also aligns with the structure of ATA that contains three carboxylate
moieties (presumably anionic at pH 7.0). Testing this hypothesis, anthraquinone-2carboxylic acid was analyzed for its inhibitory activity of NgPatB (Figure 19), however no
inhibition was observed up to 500 µM. Three structural analogues of ATA were then
tested including 5,5’-dimethylsalicylic acid, 5-methylsalicylic acid, and the parent
compound of ATA, aurin (a.k.a. p-Rosolic acid; Figure 19). Interestingly, while no
structural analogues of ATA demonstrated strong inhibition of NgPatB, a pattern was
recognized where the relative inhibition increased in the order of aurin ≤ 5methylsalicylic acid < 5,5’-dimethylsalicylic acid << aurintricarboxylic acid. Considering
the presumed importance of anionic character and the structures of these compounds, it
is perceived that inhibition increases proportional to the number of carboxylate groups
where 0 ≤ 1 < 2 << 3. Interestingly, purpurin does not contain a carboxylate group, but
the presence of at least one oxyanion on the anthraquinone substructure presumably
plays the same role as the carboxylate group(s) on aurintricarboxylic acid. It is unclear
under these considerations why anthraquinone-2-carboxylic acid does not inhibit
NgPatB, although it suggests that the presence of a hydroxyl group at C1 and C4
together with an anionic group at C2 is required.

5.3 Structure-function-inhibition relationships of NgPatB
Previous results. Analysis of the kinetic parameters regarding acceptor
substrates determined a specificity of NgPatB to O-acetylate chitooligosaccharides with
a DP ≥3, suggesting that there are a minimum of three sugar binding sites on NgPatB,
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including the active site. Additionally, the crystal structure of NgPatB was solved by A.
Brott of the Clarke lab (Figure 21), and several variants located around the active site of
NgPatB were characterized, including S153A, F161A, W191A, R289G, and Q303G
(Figure 21D; A. Brott, personal communication). The initial characterization of these
variants identified them as predicted residues that interact and bind to substrates.

Figure 21. The structure of NgPatB, provided as a gift from A. Brott. Visual representation of (A) the
secondary structure of NgPatB displaying α-helices (cyan), β-sheets (magenta), and loops (light brown),
(B) conserved residues of PatB as identified through the multiple sequence alignment of PatB homologs
from this thesis (Figure A1, Appendix 1) and the ConSurf Server (consurf.tau.ac.il) with presumed
substrate binding sites labelled -2, -1, +1, and +2, (C) in silico and manually docked MurNAc(dipeptide)GlcNAc-MurNAc(dipeptide)-GlcNAc ligand (cyan) into the active site of NgPatB with presumed binding
sites labelled, and (D) stick representation of the catalytic residues (yellow) and selected residues (cyan)
of NgPatB; the images are a close-up view of the outlined box in A and B.
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Current studies. Based on the previous work conducted by A. Brott, I propose
that the binding site of NgPatB for PG-based acceptor substrates is comprised of four
subsites that span the catalytic center of the enzyme. These are depicted in Figure 21B
and C, and are labelled -2, -1, +1, and +2. To gain more insight into these proposed
substrate binding sites of NgPatB, I first began with a MSA of PatB proteins identified in
Gram-negative pathogens that produce O-acetylated PG (known and hypothetical;
Table 1; Figure A1, Appendix 1).48 The MSA revealed conserved and variable residues
that were mapped onto the structure of NgPatB using Consurf (consurf.tau.ac.il; Figure
21B-C), and analysed to select specific residues that are predicted to comprise the
substrate binding subsites from -2 to +2 (Figure 21B-C), and thus to be important for the
catalytic function of NgPatB through substrate binding and positioning. In hopes to gain
a deeper understanding of potential binding subsites and the residues involved, a
GlcNAc-MurNAc(dipeptide)-GlcNAc-MurNAc(dipeptide) ligand was docked onto a
structure of NgPatB in silico, aiding only as a reference to support the presumed binding
subsites (Figure 21C). Interestingly, the oligopeptide chains of the MurNAc groups could
be positioned appropriately to interact with surface residues on NgPatB that are located
in close proximity to the SGNH consensus sequence blocks including any near Block I:
Gln128, Gly129; Block II: Asn148, Leu149, Ser150, Lys151, Gln152, Phe161, Phe162,
Thr167; and Block V: Gln303, and Lys304. All of these residues are conserved across
nearly all aligned species, except for the more variable Lys304 sharing the position
mainly with Gln or Arg (Figure A1, Appendix 1). However, given that the in silico docking
of the GlcNAc-MurNAc(dipeptide)-GlcNAc-MurNAc(dipeptide) ligand is not reliable, a
structure of NgPatB in complex with a similar ligand is required to determine substrate
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binding residues with confidence. The complex shown in Figure 21C strictly served as a
reference upon which theoretical considerations were discussed. Based on these
theoretical considerations, the kinetic parameters of esterase and transferase activity of
NgPatB variants including Q128G, Q152A, and K293A, in addition to WT (Figure 21D)
were determined using 0-5.0 mM pNP-Ac and 0.02-2.0 mM tetraacetyl chitotetraose
(Table 6). While all three variants reduce the catalytic efficiency of esterase activity, the
increased Km value of the K293 replacement suggest that this residue is important for
binding of the acetyl-donor substrate. The same observations hold true for transferase
activity among the Q152 replacement, with a significant increase in Km and decrease in
catalytic efficiency, indicating the importance of this residue for binding of the acetylacceptor. Interestingly, the replacement of Q128 with Gly increased the affinity of
tetraacetyl chitotetraose, yet significantly decreased the turnover number. These data
suggest the role that Q128 may play to control the binding interactions of the acetylacceptor without hindering the ability of NgPatB to turnover the acetylated product.
Notably, the transferase activity of (K293A)NgPatB was abolished. Together with the
Q128G, Q152A, and K293A NgPatB variants, Q152NSUMO and Q152ESUMO were also
produced and characterized for their ability to hydrolyze 3.5 mM pNP-Ac and acetylate
Table 6. Kinetic parameters of NgPatB variants.
± denotes standard deviation, n.d denotes not detected.
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1.0 mM tetraacetyl chitotetraose to offer insight into the role that the length of this
residue and its functional group serve for both acetyl-donor and/or acetyl-acceptor
binding interactions (Table 7). The Q152N and Q152E variants were purified with an
appended His6-SUMO tag due to issues regarding enzyme stability after cleavage of the
SUMO tag. The SUMO tag presumably does not interfere the activity of NgPatB since it
is appended to the C-terminus, and thus located far away from the active site and
sterically hindered by NgPatB from interfering with substrate binding, hence a direct
comparison between NgPatB and NgPatBSUMO constructs were applicable. For a
comprehensive analysis, I also characterized the NgPatB variants that were provided to
me as a gift from A. Brott, including S153A, F161A, R289G, and Q303G (Figure 21D;
Table 2). Unfortunately, the (W191A)NgPatB variant was unsuccessfully purified and
consequently could not be characterized or included in any further analyses. This is
likely due to precipitation of the protein upon dialysis into 20 mM sodium phosphate, pH
7.8, lacking L-arginine, after the initial purification through IMAC. All but two of the
variants demonstrated a significant rate difference of pNP-Ac hydrolysis compared to
that of WT NgPatB; the Q152NSUMO variant, bearing the same side-chain functional
group as Gln but one carbon shorter in length, led to a significant decrease in esterase
Table 7. Specific activities and inhibition of NgPatB variants.
± denotes standard deviation.
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activity, while Q152ESUMO, bearing a carboxylate side-chain functional group in place of
the amide on Gln, led to an increase in esterase activity (Table 7). The explanation for
these results is still unclear, but possibly suggests the importance of the residue at this
position for substrate binding and access of the substrate and water into the active site.
To determine the transferase ability of the variants, mass spectrometry was
utilized to confirm that the newly derived variants Q128G, Q152A, and K293A were able
to transfer acetyl groups to tetraacetyl chitotetraose, and that any observable loss of
activity was in fact due to the replaced residue and not attributed to improper structural
folding (Figure 22). The data presented in Table 7 indicate that residues Q128, Q152,
S153, F161, K293, and Q303 play a significant role in the transferase ability of NgPatB
when comparing respective specific activities to that of WT NgPatB. Perhaps most
significantly, the replacement of K293, located in the presumed -2 subsite of NgPatB
(Figure 21B-C), with Ala nearly abolished transferase activity. Additionally, purification
of (K293A)NgPatB was difficult due to sudden precipitation of the enzyme after isolating
it from cellular debris and incubating with the Ni2+-NTA resin, suggesting that K293 is
important for protein stability. Notably, K293 is a considerably variable residue among
PatB homologs, and the position is shared among other residues, mainly involving Asp
and Gly (Figure A1, Appendix 1). The variance at this position is surprising considering
the significant role that K293 appears to have when considering the difference between
the side-chain functional groups of Lys, Asp, and Gly. Interestingly though, there seems
to be conservation of this residue within genera, where Lys is conserved among all
aligned sequences from Neisseria and Kingella species, Asp among all aligned
sequences of Campylobacter species, and Gly among all aligned sequences of
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Figure 22. Mass spectrum of reaction produced by WT NgPatB and its variants. NgPatB variants (1.2
µM) Q128G (green), Q152A (red), and K293A (cyan), along with WT (blue) and a control lacking
enzyme (black) were incubated with 3.5 mM pNP-Ac and 1.0 mM tetraacetyl chitotetraose (GlcNAc4)
for 15 minutes. The spectra are offset by 0 (control), 5 (WT), 10 (Q152A), 15 (Q128G) and 20 (K293A)
for better relative visual representation of the peaks. Identified species of interest and their adducts are
labelled. Data were obtained using the Mass Spectrometry Facility of the Advanced Analysis Center,
University of Guelph, and presented with mMass software (mmass.org).

Photorhabdus, Proteus, Providencia, and Xenorhabdus species. The aligned
sequences of Moraxella species contain a small residue with Gly, Ser, or Thr, and
aligned sequences of Helicobacter species are more variable with any of the protic
residues including Lys, Asp, Gln, Asn, or Ser (Figure A1, Appendix 1). Additionally, the
replacement of Gln128 and Gln303, also positioned in the presumed -2 subsite of
NgPatB, with Gly both result in a circa. 50% reduction of transferase activity (Table 7).
Gln303 is a significantly conserved residue among PatB homologs, also displaying
conservation within genera, where Gln is conserved among all aligned sequences of
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Neisseria, Kingella, Moraxella, Photorhabdus, Proteus, Providencia, and Xenorhabdus
species, Ala in all aligned sequences of Campylobacter species except for Cys in
Campylobacter gracilis, and either Ser or Tyr in all aligned sequences of Helicobacter
species (Figure A1, Appendix 1). Gln128 is conserved across all aligned sequences
except for a Glu residue in Citrobacter youngae, Cronobacter sakazakii, Dickeya
dadantii, Eikenella corrodens, and Neisseria shayeganii, a Leu in Helicobacter pylori,
and an Asp in Zymomonas mobilis (Figure A1, Appendix 1). Further analysis of the
roles that Gln128, Lys293 and Gln303 play in the function of NgPatB is required to
determine why these residues are essential for transferase activity, and to probe the
variability of these residues, particularly Lys293 and Gln303, with respect to genus. For
example, site-specific replacements of these residues that mimic other homologs of
NgPatB could offer insight into the role(s) that these residues serve regarding potential
differences between their substrates in vivo (e.g., PG) with respect to genus.
Inhibition studies. With a greater understanding of several important functional
residues of NgPatB, I sought to probe where the inhibitors aurintricarboxylic acid and
purpurin were interacting with NgPatB. To begin, I determined the Michaelis-Menten
kinetic parameters of NgPatB esterase activity using 0-2.0 mM pNP-Ac and 0-100 µM of
inhibitor (Table 8). The results indicated that, with a decline of both Vmax and Km
proportional to increasing inhibitor concentration, both ATA and purpurin are
uncompetitive inhibitors suggesting that the inhibitors are not interacting with the active
site residues (otherwise known as competitive inhibition) but rather at an allosteric site,
possibly a substrate binding site, forming an enzyme-substrate-inhibitor complex and
interrupting substrate/product turnover.
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Table 8. Kinetic parameters of NgPatB inhibition.
± denotes standard deviation.

To identify the residues that possibly interact with each inhibitor and thus are
presumably responsible for the observed inhibition, potential allosteric residues were
replaced by site-directed mutagenesis of ngpatB and the generated variants were
probed with 10 µM ATA and 30 µM purpurin to determine their relative esterase and
transferase activity. The specific amount of inhibitor used for these kinetic analyses was
based both on their previously determined IC50 values and preliminary results, allowing
for a significant amount of control activity to analyze results with greater confidence.
The NgPatB variants tested included Q128G, Q152A, Q152NSUMO, Q152ESUMO, S153A,
F161A, R289G, K293A, and Q303G, in addition to WT (Table 7). These variants were
selected because they represented potentially important residues for transferase activity
and are likely involved in substrate binding based on examination of the surface area of
NgPatB around its catalytic residues (Figure 21D). To control for the loss of activity
imparted by the site-specific replacements alone, control reactions were conducted
without inhibitor (Table 7 – ‘Specific activity’) and compared to the activity of WT
NgPatB (‘Relative activity (no inhibitor)’). Reactions that included inhibitor were then
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compared against the respective variants’ baseline activity (‘Relative activity (10µM
ATA)’ and ‘Relative activity (30µM purpurin)’) to determine whether inhibition was
occurring. It was presumed that a loss of activity with inhibitor present (low % relative
activity) suggests that the replaced residue does not contribute significantly to inhibitor
binding, while the converse would also hold; no loss of activity in the presence of
inhibitor (high % relative activity) suggests that the replaced residue does interact with
the inhibitor. From the data presented in Table 7, it would appear that replacement of
Ser153 did not impact the extent of inhibition of NgPatB by either ATA or purpurin. In
contrast, replacement of Lys293 with Ala abolished the inhibitions. A similar effect on
the extent of inhibition was observed with the replacement of Gln152 with either Asn or
Glu. However, it should be noted that replacement of Gln152 with the latter two residues
also affected the baseline esterase activity of the respective variants in the absence of
inhibitors compared to WT enzyme (30% and 122% relative esterase activity,
respectively), while (Q152A)NgPatB retained both baseline activity and susceptibility to
inhibition by the two compounds compared to WT. Replacement of Gln128 and Gln303
with Gly had a partial effect on both the baseline activity of the variant and the extent of
inhibitions, though the latter was more pronounced. Finally, replacement of Phe161 with
Ala and Arg289 with Gly appeared to make the variants more susceptible to inhibition
by the two compounds compared to WT, while also affecting baseline activity, albeit to a
lesser extent. Taken together, these data suggest that both ATA and purpurin bind at
the presumed -2 subsite of NgPatB, involving Gln128, Lys293 and Gln303, to hinder
access of the pseudo-substrates used to assay the enzyme. This is in keeping with the
earlier finding that the presence of an anion on the inhibitors is essential for inhibition.
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Thus, ionic and possibly H-bonding interaction(s) occur between the side chains of
Lys293 and Gln128/Gln303, respectively, and the oxyanion substituents of the
inhibitors.

6. Conclusions
Experts project that by 2050, 10 million lives will be lost annually as a result of
antimicrobial resistant infections, surpassing all current leading causes of death, and
costing the global economy $100 trillion USD on healthcare efforts. Many pathogenic
bacteria, including several priority pathogens outlined by the WHO and CDC, produce
O-acetylated PG to establish infection and avoid host immune responses.
Consequently, the enzymes responsible for producing O-acetylated PG in Gramnegative and Gram-positive pathogenic bacteria, peptidoglycan O-acetyltransferase A
and B (PatA/PatB) and O-acetylpeptidoglycan transferase A (OatA), respectively, are
recognized as virulence factors and thus represent novel targets for antibiotic discovery.
While the enzymes catalyzing the O- and de-O-acetylation of PG share the same
catalytic fold and machinery, and are mechanistically indistinguishable, small changes
in or in-proximity to the active site can lead to a wide variety of substrate promiscuity, as
is seen with the Gram-positive PG O-acetyltransferases SpOatAC and SaOatAC.61,62
These details offer valuable mechanistic insights that can aid in the discovery and
development of potentially broad-spectrum small-molecule inhibitor scaffolds.
In this thesis, I first presented my results regarding the optimization of assay
conditions to monitor the esterase and transferase activity of NgPatB using pNP-Ac and
4MU-Ac as acetyl-donor substrates, and tetraacetyl chitotetraose as a surrogate PG
acetyl-acceptor. The conditions of all esterase reactions included well concentrations of
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1.2 µM NgPatB in 50 mM sodium phosphate buffer, pH 7.0, and 20% v/v DMSO.
Activity was monitored at 25ºC and analyzed between 4-10 min after the addition of the
acetyl-donor substrate. Final reaction concentrations of up to 2.0 mM 4MU-Ac was used
as the acetyl-donor substrate in esterase assays to confirm potential hit compounds
identified from the HTS by monitoring the chromogenic and fluorogenic response of the
hydrolysis product (4MU) using absorbance at 355 nm and fluorescence at λex = 390 nm
and λem = 420 nm, respectively. To analyse the kinetic parameters and inhibition of
NgPatB esterase and transferase activity, up to 5.0 mM pNP-Ac was used as the acetyldonor substrate and the chromogenic response of the hydrolysis product (pNP) was
monitored using absorbance at 405 nm. Assays measuring the transferase ability of
NgPatB were carried out in the same conditions, except with 3.5 mM pNP-Ac, 10% v/v
DMSO and between 0.02-2.0 mM tetraacetyl chitotetraose. To determine the halfmaximal inhibitory concentration (IC50) and mode of inhibition of potential inhibitors,
varying concentrations of inhibitor were incubated with NgPatB for 10 min prior to the
addition of the acetyl-donor substrate. The fluorogenic monitoring of hydrolyzed 4MU-Ac
employed in the initial high-throughput screens of NgPatB inhibition was discovered to
lead to the inherent quenching of the fluorescent response, ultimately leading to the
realization that the compounds discovered were false positives and sufficiently weaker
inhibitors of NgPatB than initially claimed.
Albeit the HTS resulted in false positives results, a stock solution of compound
89224, a benzothiazolyl-pyrazolo-pyridine from the ChemBridge Collection, lead to the
identification of a presumed degradation product as a strong inhibitor of NgPatB
esterase activity. The sample was observed under varying pH values, where upon the
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addition of HCl the sample turned a light peach colour and a precipitate formed, and the
addition of NaOH shifted the colour to green and the precipitate dissolved. These
observations are indicative of the potential role of pH on the colour, solubility, and
possibly the structural composition of this unknown compound. It is presumed that the
compound may bear a negative charge at basic pH and proposes the importance of an
anion to inhibit the activity of NgPatB. Identification of the exact chemical species
responsible for the observed inhibition remains elusive.
To address my second hypothesis, I utilized the results of a HTS completed by
Pfeffer et. al. (2012) used to identify the first known inhibitors of NgApe1,75 ultimately
discovering aurintricarboxylic acid (ATA) and purpurin as uncompetitive inhibitors
amongst the first known inhibitors of NgPatB, with IC50 values of 5.6 ± 0.4 µM and 37.2
± 7.7 µM, respectively. Overall, the presence of an anion is presumably essential to
hinder access of the pseudosubstrates used to assay the enzyme, where greater
anionic character may have increasingly greater inhibitory affects. The results found
with aurintricarboxylic acid and purpurin could prove useful in the design of stronger
inhibitors through increasing enzyme-inhibitor interactions, and the potential inhibition of
structurally related enzymes, such as homologs of NgPatB and O-acetylesterases.
My last hypothesis concerned the identification of residues on NgPatB important
for esterase and transferase activity. Using site-directed mutagenesis to replace
selected amino acids, the residues Gln128, Gln152, and Lys293 were identified in this
thesis as essential for the ability of NgPatB to acetylate the surrogate PG acetylacceptor tetraacetyl chitotetraose. Together with variants of the residues listed above,
as a gift from A. Brott in the Clarke lab I also monitored the esterase and transferase
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activity of the NgPatB variants Ser153A, Phe161A, Arg289G, and Gln303G with and
without ATA and purpurin present. It was determined that these data suggest that both
ATA and purpurin bind at the presumed -2 subsite of NgPatB, involving the residues
Gln128, Lys293 and Gln303, to hinder access of the pseudosubstrates used to assay
the enzyme. This is in keeping with the earlier finding that the presence of an anion on
the inhibitors is essential for inhibition. Thus, ionic and possibly H-bonding interactions
occur between the side chains of Lys293 and Gln128/Gln303, respectively, and the
oxyanion substituents of the inhibitors. The inhibitors presented in this thesis
presumably only inhibit enzymes containing Lys and Gln residues at the presumed -2
subsite of NgPatB. Further work is required to identify broad spectrum inhibitor(s) to
inhibit other structurally related enzymes, such as homologs of Ape1 and OatAC where
a Lys or Gln residue may not be positioned in the presumed -2 subsite.
Moreover, the kinetic parameters of esterase and transferase activity of NgPatB
variants including Q128G, Q152A, and K293A, in addition to WT were determined.
While all three variants reduce the catalytic efficiency of esterase activity, the results
suggest that Lys293 is important for binding of the acetyl-donor substrate, while Gln152
is important for binding of the acetyl-acceptor. Interestingly, the replacement of Gln128
with Gly increased the affinity of the acetyl-acceptor, yet significantly decreased the
turnover number, suggesting that Gln128 may control the binding interactions of the
acetyl-acceptor without hindering the ability of NgPatB to turnover the acetylated
product.
Notably, there was a significant decrease in transferase activity (circa. 50%) in
the NgPatB Gln128 and Gln303 replacements, while the activity of the Lys293
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replacement was abolished. Interestingly, Gln128 and Gln303 are conserved across
nearly all aligned sequences of PatB in this thesis, while Lys293 is considerably
variable, albeit there seems to be conservation of these residues within genera. Further
analysis of the roles that Gln128, Lys293 and Gln303 play in the function of NgPatB is
required to determine why these residues are essential for transferase activity, and to
probe the variability of these residues, particularly Lys293 and Gln303, with respect to
genus.
This thesis serves as a foundation upon which novel broad-spectrum inhibitors of
PG O-acetyltransferases and O-acetylesterases can be derived using the identified
underlying scaffolds presented, including aurintricarboxylic acid, purpurin, and the
presumed degradation product of compound 89224 from the ChemBridge Collection,
ultimately allowing the possibility to end the antibiotic “discovery void” and mitigate the
impending threats of antimicrobial resistance.
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Appendix 1

Figure A1. Page 1/6. Multiple sequence alignment of PatB sequences identified in Gram-negative
pathogens that produce O-acetylated PG (known and hypothetical from Table 1). The reference
secondary structure is depicted using the structure of NgPatB provided as a gift from A. Brott. The
sequence of NgPatB used in this multiple sequence alignment is lacking 100 amino acids from the Nterminal of the WT sequence, so the amino acids displayed on the MSA appear 100 residues short of
what is discussed in this thesis. Solid red residues are strictly conserved across all species. Yellow stars
depict catalytic triad residues, blue stars depict oxyanion hole residues, and green circles depict the
variant residues used in this thesis.
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Figure A1. MSA page 2/6.
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Figure A1. MSA page 3/6.
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Figure A1. MSA page 4/6.
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Figure A1. MSA page 5/6.
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Figure A1. MSA page 6/6.
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Figure A2. Dose-dependent inhibition of NgPatB esterase activity by esculetin, esculin, purpurin,
aurintricarboxylic acid, and ellagic acid. The hydrolysis of 3.5 mM pNP-Ac (black) was monitored by
absorbance at 405 nm. The hydrolysis of 1.0 mM 4MU-Ac was monitored by fluorescence at λex = 390 nm
and λem = 420 nm (blue), and absorbance at 355 nm (red).
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